Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the first patient enrolled in the first-in-human trial of CHM CDH17 has been dosed. …
Chimeric says first patient dosed in trial of CDH17-directed CAR-T cell therapy
August 28, 2024 Australian Biotech
Latest Video
New Stories
-
ENA respiratory secures extension of US funding for novel prophylactic antiviral
September 8, 2024 - - Latest News -
Groups welcome wider access to shingles vaccine for immunocompromised patients
September 6, 2024 - - Latest News -
CSL announces sale of Wuhan plasma collection and fractionation operations
September 5, 2024 - - Latest News -
The 'Week in Review' Podcast - 6 September
September 5, 2024 - - Podcast -
Pfizer-backed initiative boosts Aboriginal and Torres Strait Islander pharmacy leadership
September 5, 2024 - - Latest News -
An increasingly busy ministerial agenda risks squeezing out other issues
September 5, 2024 - - Latest News -
Groups collaborate on the development of new opioid safety toolkit
September 5, 2024 - - Latest News